Rectification Of Typographical Error In Press Release - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd (BSE: 539561, formerly Roxy Exports Limited) issued a corrected press release for its Rights Issue, fixing a date typo (April 23 changed to April 28). The Rights Issue size is ₹49.19 crores at ₹1 per share, in the ratio of 61 rights shares for every 50 shares held. The issue opens on April 30, 2025 and closes on May 14, 2025, with the renunciation window running from April 30 to May 9. Funds will be used for working capital, R&D labs (focused on CNS, metabolic, and oncology therapies), production scaling, and global expansion. The capital raise follows a recent ₹182.7 crore agreement with a UK-based pharmaceutical partner, signaling international growth ambitions.
Existing shareholders can subscribe at ₹1 per share (well below the ₹1.79 closing price on April 25), offering attractive entry to increase their holding, but the 61:50 ratio will result in significant share dilution for non-participants.